Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro.
One of the most striking features of inflammatory arthritis is the hyperplasia of synovial fibroblasts. It is not known whether the massive synovial hyperplasia characteristic of rheumatoid arthritis is due to the proliferation of synovial fibroblasts or to defective apoptosis. It has been found that glutamate receptor antagonists inhibit proliferation of different human tumour cells and the anticancer potential of glutamate receptor antagonists was suggested. Here, we investigated the effect of glutamate receptor antagonists and selected antirheumatic drugs on proliferation of synoviocytes in vitro. Experiments were conducted on rabbit synoviocytes cell line HIG-82 obtained from American Type Culture Collection (Menassas, VA, USA). Cell proliferation was assessed by means of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The IC50 value (the concentration of drug necessary to induce 50% inhibition) together with confidence limits was calculated. Glutamate receptor antagonists, 1-(4-aminophenyl)-3,5-dihydro-7,8-dimethoxy-4H-2,3-benzodiazepin-4-one (CFM-2), riluzole, memantine, 1-4-aminophenyl-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI 52466), dizocilpine, ketamine and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), inhibited proliferation of synoviocytes with the following IC50 values (in mM): 0.014, 0.017, 0.065, 0.102, 0.15, 0.435 and 1.16, respectively. Antirheumatic drugs, celecoxib, diclofenac, nimesulide, sulfasalazine, naproxen and methotrexate, inhibited proliferation of synoviocytes with the following IC50 values (in mM): 0.0043, 0.034, 0.044, 0.096, 0.385 and 1.123, respectively. Thus, the antiproliferative potential of glutamate receptor antagonists is comparable to that of antirheumatic drugs.
Department of Rheumatology and Connective Tissue Diseases, Medical University, Jaczewskiego 8, 20-950 Lublin, Poland. jolanta.turska@am.lublin.pl
Jolanta
J
Parada-Turska
Wojciech
W
Rzeski
Maria
M
Majdan
Martyna
M
Kandefer-Szerszeń
Waldemar A
WA
Turski
D000818:Animals; D018501:Antirheumatic Agents / Q000494:pharmacology*; D001569:Benzodiazepines / Q000494:pharmacology; D001570:Benzodiazepinones / Q000494:pharmacology; D000068579:Celecoxib; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D004008:Diclofenac / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D020128:Inhibitory Concentration 50; D008727:Methotrexate / Q000494:pharmacology; D009288:Naproxen / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D012460:Sulfasalazine / Q000494:pharmacology; D013449:Sulfonamides / Q000494:pharmacology; D013583:Synovial Membrane / Q000166:cytology*
D018501:Antirheumatic Agents; D001570:Benzodiazepinones; C119033:CFM 2; D018691:Excitatory Amino Acid Antagonists; D011720:Pyrazoles; D011810:Quinoxalines; D013449:Sulfonamides; C061950:GYKI 52466; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; D001569:Benzodiazepines; D004008:Diclofenac; D012460:Sulfasalazine; D009288:Naproxen; D000068579:Celecoxib; C012655:nimesulide; D008727:Methotrexate